Results 221 to 230 of about 274,980 (287)
Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort. [PDF]
PituitaryYuen KCJ, Vila G, Bernabeu I, Buchfelder M, Freda P, Henocque R, Torre D, Maffei P, Strasburger CJ, Neggers S, Brue T. +10 moreeuropepmc +1 more sourceTargeting Cancer Cachexia: A Mechanistic Evaluation of Anti-GDF-15 Antibody-Based Combination Therapies. [PDF]
J Cachexia Sarcopenia MuscleBreen DM, Joaquim S, Paulhus BL, Bennett D, Bernardo B, Collins S, Esquejo RM, Kim-Muller JY, Lin L, Peloquin M, Wu Z, Qiao S, Stansfield JC, Zhang BB, Rossulek MI. +14 moreeuropepmc +1 more sourceNeoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial
International Journal of Cancer, EarlyView.Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...Benedikt Niedermaier, Tilmann Bochtler, Florian Eichhorn, Raffaella Griffo, Laura V. Klotz, Michael Allgäuer, Albrecht Stenzinger, Helge Bischoff, Marc A. Schneider, Petros Christopoulos, Uwe Haberkorn, Claus Peter Heussel, Inka Zoernig, Felix J. F. Herth, Michael Thomas, Alexander Rölle, Hauke Winter, Axel Benner, Dirk Jaeger, Martin E. Eichhorn +19 morewiley +1 more sourceThe Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition
International Journal of Cancer, EarlyView.Although immune checkpoint inhibitors (ICI) have transformed metastatic melanoma treatment, thromboembolic events (TEEs) remain a serious complication. Moreover, existing risk assessment models were developed prior to ICI use and lack clinical validation.Tim Zell, Julian Kött, Noah Zimmermann, Greta Ancker, Alexander T. Bauer, Daniel J. Smit, Glenn Geidel, Julian C. Gerwers, Thomas Renné, Sebastian A. Wohlfeil, Jochen Utikal, Stefan W. Schneider, Christoffer Gebhardt +12 morewiley +1 more sourceRapid Onset of Response in Adults with Dermatomyositis Receiving Dazukibart: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study. [PDF]
Clin Cosmet Investig DermatolAggarwal R, Peeva E, Fiorentino DF, Vleugels RA, Mangold AR, Werth VP, Oemar BS, Rath JN, Sloan A, Chu M. +9 moreeuropepmc +1 more sourceChemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial
International Journal of Cancer, EarlyView.Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler +16 morewiley +1 more sourceThe Relevance of Curative‐Intent Metastasectomy in Colorectal Cancer Patients: Real‐World Insights From a Certified Comprehensive Cancer Center in Germany
International Journal of Cancer, EarlyView.Patients with metastatic colorectal cancer who are ineligible for upfront metastasectomy may still become candidates for secondary metastasectomy with curative intent following response to primary chemotherapy. However, most studies dichotomize metastatic colorectal cancer into resectable and unresectable disease.Julian W. Holch, Jo‐Ann Eisenburger, Antony Weber, Iris Kammermeier‐Wehlau, Yannick Wiberg, Fabian Allmendinger, Kathrin Heinrich, Lena Weiss, C. Benedikt Westphalen, Victoria Krenmayr, Klara Dorman, Danmei Zhang, Theres Fey, Karin Berger‐Thürmel, Ulrich Wirth, Florian Kühn, Michael von Bergwelt‐Baildon, Jens Werner, Volker Heinemann +18 morewiley +1 more sourceSafety and effectiveness of voxelotor in individuals with sickle cell disease in the RETRO and PROSPECT US registries. [PDF]
Blood AdvAndemariam B, Shah N, Ershler WB, Ivy ED, Darbari DS, Anderson A, Rai P, Wun T, Yu CR, Purdie DM, Valenzuela CM, Xu M. +11 moreeuropepmc +1 more sourceMolecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany
International Journal of Cancer, EarlyView.Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt +26 morewiley +1 more sourceA Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18-64 Years of Age (Preliminary Results). [PDF]
Vaccines (Basel)Dadhe R, Gayed J, Iqbal M, Solan R, Wu H, Ma H, Xu X, Mensa FJ, Belanger T, Cooper D, Mogg R, Anderson AS, Türeci Ö, Şahin U, Allen PS, Modjarrad K, Gurtman A, Lindert K. +17 moreeuropepmc +1 more source